A Phase I Trial of Concurrent RHUMAB VEGF (BEVACIZUMAB) and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 30 Jun 2009 Genentech added as trial sponsor and lead trial center as reported by ClinicalTrials.gov.
- 30 Jun 2009 Actual end date changed from Mar 2005 to Jul 2006 as reported by ClinicalTrials.gov.